SymbolXERS
NameXERIS BIOPHARMA HOLDINGS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
AddressIllinois, 60607, United States
Telephone844-445-5704
Fax
Email
Websitehttps://www.xerispharma.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001867096
Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushings syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Additional info from NASDAQ:
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushings syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

2026-08-12 20:44

Pieper Steven 🔴 sold 5.0K shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.50 Transaction Date: Aug 12, 2026 | Filing ID: 000009

Read more
2026-08-12 20:37

📋 STEVEN PIEPER (Officer) plans to sell 20K shares of XERIS BIOPHARMA HOLDINGS INC (at $8.39 each, total $168K) Filed: Aug 12, 2026 | ID: 008033

Read more
2026-08-06 11:00

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Read more
2026-07-31 11:42

New Form SCHEDULE 13G - Xeris Biopharma Holdings, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001430 <b>Size:</b> 7 KB

Read more
2026-07-23 11:30

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Read more
2026-07-17 20:20

(99% Neutral) XERIS BIOPHARMA HOLDINGS, INC. (XERS) Provides Business Update

Read more
2026-07-07 21:11

Pieper Steven 🔴 sold 45.0K shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.52 Transaction Date: Jul 06, 2026 | Filing ID: 000007

Read more
2026-07-07 20:37

📋 STEVEN PIEPER (Officer) plans to sell 28K shares of XERIS BIOPHARMA HOLDINGS, INC. (at $8.37 each, total $231K) Filed: Jul 07, 2026 | ID: 006941

Read more
2026-07-06 20:39

📋 STEVEN PIEPER (Officer) plans to sell 17K shares of XERIS BIOPHARMA HOLDINGS, INC. (at $8.28 each, total $144K) Filed: Jul 06, 2026 | ID: 006884

Read more
2026-07-03 02:40

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Read more